These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 29664606

  • 1. Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin.
    Lymperis E, Kaloudi A, Sallegger W, Bakker IL, Krenning EP, de Jong M, Maina T, Nock BA.
    Bioconjug Chem; 2018 May 16; 29(5):1774-1784. PubMed ID: 29664606
    [Abstract] [Full Text] [Related]

  • 2. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, de Jong M, Maina T, Baum RP.
    J Nucl Med; 2017 Jan 16; 58(1):75-80. PubMed ID: 27493272
    [Abstract] [Full Text] [Related]

  • 3. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
    Maina T, Bergsma H, Kulkarni HR, Mueller D, Charalambidis D, Krenning EP, Nock BA, de Jong M, Baum RP.
    Eur J Nucl Med Mol Imaging; 2016 May 16; 43(5):964-973. PubMed ID: 26631238
    [Abstract] [Full Text] [Related]

  • 4. Comparing Gly11/dAla11-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the 111In-SB3/111In-SB4 Radiotracer Pair.
    Lymperis E, Kaloudi A, Kanellopoulos P, de Jong M, Krenning EP, Nock BA, Maina T.
    Molecules; 2019 Mar 13; 24(6):. PubMed ID: 30871262
    [Abstract] [Full Text] [Related]

  • 5. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
    Chatalic KL, Franssen GM, van Weerden WM, McBride WJ, Laverman P, de Blois E, Hajjaj B, Brunel L, Goldenberg DM, Fehrentz JA, Martinez J, Boerman OC, de Jong M.
    J Nucl Med; 2014 Dec 13; 55(12):2050-6. PubMed ID: 25413139
    [Abstract] [Full Text] [Related]

  • 6. Synthesis and Evaluation of the First 68Ga-Labeled C-Terminal Hydroxamate-Derived Gastrin-Releasing Peptide Receptor-Targeted Tracers for Cancer Imaging with Positron Emission Tomography.
    Wang L, Kuo HT, Chen CC, Chapple D, Colpo N, Ng P, Lau WS, Jozi S, Bénard F, Lin KS.
    Molecules; 2024 Jun 28; 29(13):. PubMed ID: 38999054
    [Abstract] [Full Text] [Related]

  • 7. Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC, Cho EH, Kim JJ, Choi SM, Lee Sy, Nam SS, Park UJ, Park SH.
    Nucl Med Biol; 2015 Feb 28; 42(2):131-6. PubMed ID: 25457455
    [Abstract] [Full Text] [Related]

  • 8. In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies.
    Chatalic KL, Konijnenberg M, Nonnekens J, de Blois E, Hoeben S, de Ridder C, Brunel L, Fehrentz JA, Martinez J, van Gent DC, Nock BA, Maina T, van Weerden WM, de Jong M.
    Theranostics; 2016 Feb 28; 6(1):104-17. PubMed ID: 26722377
    [Abstract] [Full Text] [Related]

  • 9. Amide-to-triazole switch vs. in vivo NEP-inhibition approaches to promote radiopeptide targeting of GRPR-positive tumors.
    Maina T, Kaloudi A, Valverde IE, Mindt TL, Nock BA.
    Nucl Med Biol; 2017 Sep 28; 52():57-62. PubMed ID: 28636973
    [Abstract] [Full Text] [Related]

  • 10. A comparative PET imaging study of 44gSc- and 68Ga-labeled bombesin antagonist BBN2 derivatives in breast and prostate cancer models.
    Ferguson S, Wuest M, Richter S, Bergman C, Dufour J, Krys D, Simone J, Jans HS, Riauka T, Wuest F.
    Nucl Med Biol; 2020 Sep 28; 90-91():74-83. PubMed ID: 33189947
    [Abstract] [Full Text] [Related]

  • 11. Comparative evaluation of the new GRPR-antagonist 111 In-SB9 and 111 In-AMBA in prostate cancer models: Implications of in vivo stability.
    Lymperis E, Kaloudi A, Kanellopoulos P, Krenning EP, de Jong M, Maina T, Nock BA.
    J Labelled Comp Radiopharm; 2019 Aug 28; 62(10):646-655. PubMed ID: 30963606
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides.
    Mansi R, Wang X, Forrer F, Kneifel S, Tamma ML, Waser B, Cescato R, Reubi JC, Maecke HR.
    Clin Cancer Res; 2009 Aug 15; 15(16):5240-9. PubMed ID: 19671861
    [Abstract] [Full Text] [Related]

  • 13. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
    Dalm SU, Bakker IL, de Blois E, Doeswijk GN, Konijnenberg MW, Orlandi F, Barbato D, Tedesco M, Maina T, Nock BA, de Jong M.
    J Nucl Med; 2017 Feb 15; 58(2):293-299. PubMed ID: 27609789
    [Abstract] [Full Text] [Related]

  • 14. In vivo enzyme inhibition improves the targeting of [177Lu]DOTA-GRP(13-27) in GRPR-positive tumors in mice.
    Marsouvanidis PJ, Melis M, de Blois E, Breeman WA, Krenning EP, Maina T, Nock BA, de Jong M.
    Cancer Biother Radiopharm; 2014 Nov 15; 29(9):359-67. PubMed ID: 25286347
    [Abstract] [Full Text] [Related]

  • 15. In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer.
    Bakker IL, van Tiel ST, Haeck J, Doeswijk GN, de Blois E, Segbers M, Maina T, Nock BA, de Jong M, Dalm SU.
    Mol Imaging Biol; 2018 Dec 15; 20(6):973-983. PubMed ID: 29556947
    [Abstract] [Full Text] [Related]

  • 16. Comparison of biological properties of [177 Lu]Lu-ProBOMB1 and [177 Lu]Lu-NeoBOMB1 for GRPR targeting.
    Rousseau E, Lau J, Zhang Z, Zhang C, Kwon D, Uribe CF, Kuo HT, Zeisler J, Bratanovic I, Lin KS, Bénard F.
    J Labelled Comp Radiopharm; 2020 Feb 15; 63(2):56-64. PubMed ID: 31715025
    [Abstract] [Full Text] [Related]

  • 17. GRPr Antagonist 68Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naïve Patients.
    Bakker IL, Fröberg AC, Busstra MB, Verzijlbergen JF, Konijnenberg M, van Leenders GJLH, Schoots IG, de Blois E, van Weerden WM, Dalm SU, Maina T, Nock BA, de Jong M.
    J Nucl Med; 2021 Nov 15; 62(11):1517-1523. PubMed ID: 33789933
    [Abstract] [Full Text] [Related]

  • 18. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.
    Mitran B, Rinne SS, Konijnenberg MW, Maina T, Nock BA, Altai M, Vorobyeva A, Larhed M, Tolmachev V, de Jong M, Rosenström U, Orlova A.
    Int J Cancer; 2019 Dec 15; 145(12):3347-3358. PubMed ID: 31077356
    [Abstract] [Full Text] [Related]

  • 19. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC, Cho EH, Kim JJ, Choi SM, Lee SY, Nam SS, Park UJ, Park SH.
    Nucl Med Biol; 2015 Mar 15; 42(3):234-41. PubMed ID: 25498002
    [Abstract] [Full Text] [Related]

  • 20. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
    Stott Reynolds TJ, Schehr R, Liu D, Xu J, Miao Y, Hoffman TJ, Rold TL, Lewis MR, Smith CJ.
    Nucl Med Biol; 2015 Feb 15; 42(2):99-108. PubMed ID: 25459113
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.